Stay updated on Setmelanotide in BBS and AS for Obesity Clinical Trial
Sign up to get notified when there's something new on the Setmelanotide in BBS and AS for Obesity Clinical Trial page.

Latest updates to the Setmelanotide in BBS and AS for Obesity Clinical Trial page
- Check2 days agoChange DetectedAlström syndrome was added to the list of study conditions, explicitly including AS in the study details.SummaryDifference0.2%

- Check9 days agoChange DetectedNo substantive changes detected; the page content appears unchanged across the two screenshots.SummaryDifference0.2%

- Check17 days agoChange DetectedAdded a new publication citation for the Phase 3 BBS trial (Argente et al.). Updated the page revision to v3.5.0 and removed the prior 'Online ahead of print' citation (v3.4.3).SummaryDifference0.2%

- Check24 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.2%

- Check31 days agoChange DetectedNo visible additions or deletions detected; the page content appears unchanged.SummaryDifference0.2%

- Check38 days agoChange DetectedAdded a new publication citation to the Publications section: Argente J, Haqq AM, Schorfheide JL, Touchot N, Huber C, Wiedemann U, Pomeroy J; Phase 3 BBS Trial Investigators. Setmelanotide in Bardet-Biedl Syndrome: A 52-Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort. Obesity (Silver Spring). 2026 Feb 17. Online ahead of print.SummaryDifference0.2%

Stay in the know with updates to Setmelanotide in BBS and AS for Obesity Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Setmelanotide in BBS and AS for Obesity Clinical Trial page.